Tag: heart desease

New trial results support treatment with Inspra (eplerenone) within first 24 hours of symptoms, in addition to standard therapy, in patients with acute STEMI without heart failure.

by PressCenter.com

April 5, 2013

Pfizer Inc. (NYSE: PFE) today announced results from the REMINDER trial showing statistically significant risk reductions in the primary composite ...

PressCenter.com is state-of-the-art Press Release Distribution Platform. PressCenter.com send and track your Press Release using our industry-leading global Media Contacts Database of a million contacts. Your Press Release will reach business news editors and journalists, in targeted sectors and territories or worldwide.

Tag: heart desease

New trial results support treatment with Inspra (eplerenone) within first 24 hours of symptoms, in addition to standard therapy, in patients with acute STEMI without heart failure.

777Funds reports progress on DeFi vault, NFT release with AMLOK FasterCapital-supported

ASTPP Advances Telecom Automation with Integrated Auto Dialer and Billing Platform

Suffescom Achieves AWS Cloud Operations Competency to Help Enterprises Run Secure Cloud Environments

DataVare Launches MBOX to NSF Converter 2.0 for Batch Conversion, Selective Export & Seamless Lotus Notes Migration

Osiz Technologies, a Blockchain Development Company, Shares Key Blockchain Trends Shaping Business in 2026

Policies

Services

Press Releases by E-Mail

Categories

Welcome Back!

Create New Account!

Retrieve your password